Compare ResMed Inc. (RMD) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vale SA — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Vale SA trades at $15.42 (market cap $65.56B). The key difference: Vale SA is far larger — about 2.1× ResMed Inc.'s market cap, and Vale SA pays the higher dividend (7.65%). Which is the better fit depends on your goals.
| RMD | VALE | |
|---|---|---|
Market Cap | $31.89B | $65.56B |
Sector | Health | Basic Materials |
52-Week High | $283.28 | $17.82 |
52-Week Low | $182.82 | $10.50 |
Enterprise Value | $31.24B | $81.80B |
Dividend Yield | 1.19% | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
VALE trades at $15.56, up 1.9% on the day, with a bullish technical signal from moving averages and a consensus price target of $16.79. Recent earnings missed estimates for Q4 2025 and Q1-Q2 2026, with net income margin declining to 5.11% in 2025. The company maintains strong operating cash flow of $8.80B and announced a $0.40 dividend for H2 2026. Iron ore demand remains stable per the CFO, while base metals growth offsets cost pressures.
VALE presents a mixed outlook: bullish technicals and analyst support contrast with earnings misses and margin compression. The stock offers value near consensus targets with dividend income, but faces risks from rising costs, volatile commodity prices, and legal liabilities from past dam incidents. Upside depends on execution in copper growth and cost control.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
